Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Datametrex has appointed Baker Tilly WM LLP as its new auditor
  • Baker Tilly is a full-service accounting, tax and advisory firm
  • Datametrex AI Limited is a technology-focused company
  • Datametrex AI Limited (DM) opened trading at C$0.18 per share

Datametrex (DM) has appointed Baker Tilly WM LLP as its new auditor following the resignation of SRCO Professional Corporation.

The company’s audit committee and board have approved the appointment of Baker Tilly effective September 20, 2021.

Baker Tilly is a full-service accounting, tax and advisory firm with offices in Vancouver and Toronto. Baker Tilly is an independent member of Baker Tilly International, a worldwide network of independent accounting and business advisory firms in 147 territories, with 33,600 professionals.

Datametrex AI Limited is a technology-focused company with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy.

Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies.

Datametrex AI Limited (DM) opened trading at C$0.18 per share.

More From The Market Herald
Field Trip Health - President, Hannan Fleiman.

" Field Trip Health (TSX:FTRP) announces three new therapy centers

Field Trip Health (FTRP) is announcing new psychedelic-assisted therapy centers in Seattle, Vancouver and Fredericton.
Levitee Labs - CEO, Pouya Farmand.

" Levitee Labs (CSE:LVT) partners with Adracare for addiction and mental health support

Levitee Labs (LVT) has signed an agreement with Adracare to develop a platform for mental health services.

" Cardiol Therapeutics (TSX:CRDL) expands phase II/III trial of CardiolRx

Cardiol Therapeutics (CRDL) is expanding its LANCER trial to include several hospital centers in Brazil, Mexico, and Canada.

" XORTX Therapeutics (CSE:XRX) closes public offering

XORTX Therapeutics (XRX) announced the closing of a US$12M public offering.